Skip to content

The Medicare GLP-1 Bridge: Access, Affordability & the Pharmacist’s Role | TWIRx

Pharmacy Podcast Network

38m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode covers major pharmacy news and features an interview with Dr. Javi Hamilton, Senior Pharmacy Director at Buzz Health, discussing medication access and the Medicare GLP-1 bridge program. The host explores pressing industry topics including a federal audit on Medicare Part D overpayments for over-the-counter drugs, supply pressures on estradiol patches, conflicting pediatric and obstetric vaccine guidelines, and a proposed CMS rule that would exclude contracted pharmacists from billing remote patient monitoring services. Dr. Hamilton breaks down how the new Medicare GLP-1 bridge program operates outside traditional Part D coverage, offering long-term weight management medications at a fixed fifty-dollar monthly copay while highlighting crucial considerations around deductibles, sustainability, and employer-sponsored retiree plans.

Listeners get a detailed look at non-traditional career paths for pharmacists and practical strategies for navigating complex policy changes and patient counseling barriers. The discussion provides clear insights into how healthcare policies impact daily pharmacy operations and why pharmacist advocacy and patient education remain essential.

  • Medicare Part D plans made nearly 588 million dollars in improper payments between 2021 and 2023 for medications transitioning from prescription to over-the-counter status. 4:40
  • The Medicare GLP-1 bridge program operates outside traditional Part D coverage with its own prior authorization and payment systems, offering eligible beneficiaries long-term weight management medication for fifty dollars per month. 23:42
  • Copayments made under the Medicare GLP-1 bridge program do not count toward a patient's Part D deductible or out-of-pocket maximum. 24:58
  • Under a proposed CMS rule for the 2027 physician fee schedule, remote patient monitoring and remote treatment management services delivered by contractors would no longer be billable. 11:19

Chapters

  1. 0:04
    Podcast Intro & Website Marketing

    Hosts introduce the episode and promote Finch Marketing’s website services for pharmacy businesses.

  2. 0:51
    Twerks Podcast Network Overview

    Hosts discuss branding, trademarking, and recruiting new hosts for the pharmacy podcast network.

  3. 4:21
    Twerks News Segment – Medicare Part D Mispayments

    Hosts report on Medicare Part D improper payments for over‑the‑counter drugs and coordination issues with CMS.

  4. 5:42
    Twerks News – Estradiol Patch Supply Issues

    Discussion of FDA and manufacturer efforts to address estradiol patch shortages and pharmacist supply chain pressures.

  5. 7:23
    Twerks News – RSV & COVID Vaccine Guidance

    Hosts explain new pediatric and obstetric RSV/COVID vaccine recommendations and the need for pharmacist clarification.

  6. 10:07
    Twerks News – Remote Patient Monitoring Rule

    Hosts cover CMS’s proposed rule that could cut pharmacist billing for RPM/RTM and encourage comment submission.

  7. 13:34
    Megan Urban – Outcomes Webinar Promotion

    Megan Urban promotes an upcoming Outcomes webinar on RX30 and encourages listeners to tune in.

  8. 14:11
    Buzz Health Bridge Program Intro

    Hosts introduce Buzz Health and explain the Bridge Program’s role in expanding access to GLP‑1 medications for Medicare beneficiaries.

  9. 21:31
    Bridge Program Details – Eligibility & Pricing

    Javi Hamilton explains how the Bridge Program operates outside Part D, its $50 copay, and implications for deductibles and out‑of‑pocket costs.

  10. 30:37
    Bridge Program Impact on Employers & Retirees

    Discussion of how employers and retirees on employer‑group plans can leverage the Bridge Program and the importance of education and sustainability.

  11. 32:18
    Pharmacist Role in Bridge Program Implementation

    Hosts outline the pharmacist’s responsibilities in counseling patients, managing access barriers, and communicating with employers.

  12. 34:11
    Closing Remarks & Upcoming Events

    Hosts wrap up the episode, promote upcoming conferences, awards, and encourage listener engagement.

Highlights

  • 4:40

    Medicare Over-The-Counter Drug Paymentsdata

    An HHS OIG audit reveals hundreds of millions in improper Part D payments for drugs that switched to over-the-counter status, highlighting coordination gaps between the FDA, CMS, and plan sponsors.

  • 5:51

    Estradiol Patch Supply Pressuresinsight

    The FDA is working with six manufacturers to increase production of transdermal patches amid rising demand, leaving pharmacists on the front lines to manage frustrated patients and communicate with prescribers.

  • 6:55

    Conflicting Respiratory Vaccine Guidelinesinsight

    New RSV and COVID recommendations from professional societies create clinical confusion for pharmacists who must navigate unsettled federal guidance while counseling patients.

  • 11:19

    Proposed CMS Rule Threatens RPMstrategy

    A proposed change in the 2027 Medicare physician fee schedule would restrict remote patient monitoring and treatment management billing exclusively to clinical staff employed directly by the practice, excluding contractors.

  • 20:06

    Transitioning to Industry Leadershipstory

    Dr. Javi Hamilton shares her career journey from clinical hospital pharmacy and burnout during COVID to becoming Senior Pharmacy Director at Buzz Health, focusing on health equity and medication access.

  • 23:42

    Structure of the GLP-1 Bridgeinsight

    The Medicare bridge program provides long-term weight management GLP-1 medications at a fixed fifty-dollar monthly copayment, running separately from standard Part D benefits until December 2027.

  • 26:51

    Employer Group Waiver Plan Confusioninsight

    Retirees covered under employer-sponsored Part D plans often remain unaware of whether they qualify for specialized bridge programs, creating an educational opening for pharmacists and benefit managers.

Quotes

  • “Medicare part D paid nearly 588 million for ineligible over the counter drugs.”
    Unnamed speaker · 4:21
  • “I think that's huge, you know, like, you don't want to wait toward the end of the year, or even mid-year, and somebody has been paying like $500 for this medication, and they realize that, you know, why my deductible is not going anywhere.”
    Unnamed speaker · 31:24
  • “We need more people like you. Thank you.”
    Unnamed speaker · 34:08
  • Finch Marketing 0:26–0:51
  • Outcomes 13:31–14:09
  • Finch Marketing 15:15–15:38

About this episode

TWIRx NEWS 1. Medicare Part D Paid Nearly $588 Million for Ineligible OTC Drugs A federal audit found that Medicare Part D sponsors made approximately $587.7 million in ineligible payments from 2021 through 2023 for medications that had effectively transitioned from prescription to over-the-counter status. The HHS Office of Inspector General cited outdated FDA information and the lack of a clear CMS rejection timeline as major contributors. Why it matters: This exposes a serious coordination problem across FDA data, manufacturers, CMS, health plans and pharmacy claims systems. Pharmacists may see the rejection or payment issue at the counter, but the failure often begins far upstream. Read the Fierce Healthcare reportRead the HHS-OIG audit 2. FDA Responds to Estradiol Patch Supply Pressure The FDA is working with six manufacturers to improve access to estradiol transdermal patches amid increased demand. While FDA has not declared a national shortage, availability varies by product, strength and geographic area. Manufacturers are increasing production through larger batches, added shifts and expanded capacity. Why it matters: Pharmacists are again serving as the front line of a supply-chain challenge—helping patients locate medication, coordinating with prescribers and identifying alternatives. Read the Reuters reportRead the FDA update 3. New RSV and COVID-19 Guidance Released The American Academy of Pediatrics and American College of Obstetricians and Gynecologists have issued updated recommendations for RSV and COVID-19 protection during the 2026–2027 respiratory season. Why it matters: Pharmacists may face conflicting recommendations, patient confusion and questions about eligibility. Clear counseling and coordination with pediatric and obstetric providers will be critical. Read the Pharmacy Times report SPECIAL ANNOUNCEMENT FROM OUTCOMES A special update from Megan Urban and Outcomes. Outcomes is highlighting new enhancements to its Rx30 pharmacy management platform, including a refreshed user experience, automated data-entry capabilities and support from a dedicated Client Success Team. The program will explore how these updates can streamline pharmacy workflows, save time and support greater focus on patient care. Presented by: Dalia Rios and Kaley LesterSeptember 9, 2026 — 1:30 p.m. ET Register here FEATURED CONVERSATION Building a Bridge to GLP-1 Access Our featured guest is HaVy Ngo-Hamilton, PharmD, RPh, Senior Pharmacy Director at Buzz Health. HaVy works at the intersection of pharmacy, healthcare technology, medication affordability and prescription access. Buzz Health operates platforms including BuzzRx, RxCompare and RxAffect, with a focus on helping connect patients, pharmacies, prescribers and prescription pricing information. That makes today’s discussion particularly timely. THE MEDICARE GLP-1 BRIDGE CMS launched the Medicare GLP-1 Bridge on July 1, 2026, to provide eligible Medicare Part D beneficiaries access to selected GLP-1 medications for weight management. The demonstration runs through December 31, 2027. Eligible beneficiaries pay $50 for a monthly supply, while the program operates outside the traditional Part D payment flow through centralized prior authorization, claims adjudication and pharmacy payment. Eligible therapies currently include: Foundayo®Wegovy®Zepbound® The bigger issue is not simply GLP-1 coverage. It is how healthcare connects eligibility, affordability, prior authorization, pharmacy workflow and patient access. The central question for today’s discussion: Can we create a medication-access system where patients know whether they can obtain and afford their therapy before they reach the pharmacy counter? CLOSING THOUGHT The Medicare GLP-1 Bridge is more than another federal drug program. It is a real-world test of how healthcare can better connect coverage, affordability, prior authorization and pharm

Transcript

0:00
38:32

5,454 words · 6 speakers

Topics

  • twerks
  • CMS
  • Medicare
  • Buzz Health
  • FDA
  • GLP-1
  • Remote Patient Monitoring
  • Pharmacy Podcast Network
  • Maine
  • Portland

Page updated · transcript and summary are machine-generated